Bank of America Maintains Bullish Stance on Eli Lilly Despite Lowered Price Target
Bank of America (BofA) maintains a Buy rating on Eli Lilly (LLY) despite lowering its price target to $1,133, citing strong sales and earnings from obesity and diabetes treatments. The firm acknowledges risks such as tirzepatide safety concerns and competition but remains optimistic about Eli Lilly's long-term growth in the GLP-1 market.
Tickers: $LLY
Topics: analyst rating Eli Lilly GLP-1 pharmaceuticals stock price target